Supplementary Figure 10: Sickle cell disease correction by HSCT post CD45–SAP conditioning | Nature Biotechnology

Supplementary Figure 10: Sickle cell disease correction by HSCT post CD45–SAP conditioning

From: Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin

Supplementary Figure 10

(a) HSC depletion in sickle disease mice 8 days post-administration of various doses of CD45-SAP. Data represent the mean ± SEM (n = 3 mice/dose, assayed individually). (b) Red blood cell (RBC) counts, (c) hemoglobin levels, (d) hematocrit levels, and (e) reticulocyte frequency for wild type control, sickle disease and the 3 groups of CD45-SAP conditioned and transplanted sickle mice 4 months post transplantation of 107 bone marrow cells from wild-type donor. Data in (b-e) represent the mean ± SEM (n = 6 mice/group, assayed individually). (f) Native-PAGE analysis of normal (Hba) and sickle (Hbs) hemoglobin protein in blood from wild-type control mice, sickle mice and groups A-C mice (two representative mice from each group). (g) Spleen mass 4 months post transplantation for wild type control, sickle disease and the 3 groups of CD45-SAP conditioned and transplanted sickle mice. Data represent the mean ± SEM (n = 3 mice/group, assayed individually). * indicates p value <0.05; ** indicates p value <0.01; *** indicates p value <0.001; n.s. indicates not significant (p value >0.05). Statistics calculated using two-sided unpaired t test.

Back to article page